SOFOSBUVIR / VELPATASVIR (EPCLUSA)
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed dose combination medication for the treatment of hepatitis C. It combines sofosbuvir and velpatasvir.It is more than 90% effective for hepatitis C genotypes one through six.
Medical Uses:
A single tablet regimen is used for adults with genotype 1–6 chronic hepatitis C virus (HCV) infection.
Images:
Side Effects:
Common side effects (in more than 10% of people) are headache, fatigue and nausea. Breathing difficulty Sleeping trouble Loss of appetite
Precautions:
All patients should be tested for evidence of current/prior HBV infection before starting this drug HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. HCV/HBV-coinfected patients should be monitored for hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.